XTalks

JANUARY 20, 2025

While the deal required regulatory divestitures, including the sale of Otezla (apremilast) to Amgen for $13.4 Blockbuster products like Botox (botulinum toxin) and Restasis (cyclosporine) provided Actavis with high-margin, branded revenue streams that complemented its existing generic drug business.

Marketing 104

Marketing Botox Life Science Pharma Companies 104

XTalks

NOVEMBER 1, 2024

This year, key players like Roche, AbbVie and Janssen have bolstered their offerings with therapies targeting multiple sclerosis (MS), migraines, schizophrenia and more, each leveraging unique mechanisms of action and clinical benefits that resonate with patient needs and treatment gaps.

FDA Approval 85

FDA Approval Drugs Botox Sales 85

pharmaphorum

NOVEMBER 18, 2020

The decision is based on trials comparing Emgality with placebo which showed that the antibody halved the number of monthly migraine headache days for up to 40% of adults with migraine who had previously tried three or more prior medicines, such as Allergan’s Botox (botulinum toxin type A) or topiramate.

Sales 96

Sales Botox Antibody Drugs 96

pharmaphorum

NOVEMBER 18, 2020

The decision is based on trials comparing Emgality with placebo which showed that the antibody halved the number of monthly migraine headache days for up to 40% of adults with migraine who had previously tried three or more prior medicines, such as Allergan’s Botox (botulinum toxin type A) or topiramate.

Sales 94

Sales Botox Antibody Drugs 94

pharmaphorum

MARCH 18, 2022

Allergan fell foul of the regulations for a number of LinkedIn and Instagram posts promoting Botox (botulinum toxin type A) to the public by the chief executive of aesthetics clinic – described in his profile as an ‘Allergan mentee’, which were also liked or commented on by employees of the company.

Botox 64

Botox Medicine Nurses Sales 64

XTalks

AUGUST 2, 2023

Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. billion in pharmaceutical sales from 2021. In contrast, several drugs experienced sale declines, such as Remicade (infliximab), an old immunology medication that continues to decline due to the rise of biosimilars since 2016.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

FEBRUARY 4, 2021

– Full-Year Global Net Revenues from the Aesthetics Portfolio Were $2.590 Billion; Global Botox Cosmetic Net Revenues Were $1.112 Billion. – Full-Year Global Net Revenues from the Neuroscience Portfolio Were $3.496 Billion; Global Botox Therapeutic Net Revenues Were $1.387 Billion; Global Vraylar Net Revenues Were $951 Million.

Botox 52

Botox Production Sales Cosmetics 52